Quality Assurance in Ovarian Cancer (QS-OVAR)

• Conditions: C56; Malignant neoplasm of ovary

• Registration Number: DRKS00027253
• Lead Sponsor: AGO Research GmbH, AGO Studiengruppe

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 781

Inclusion Criteria

Age at least 18 years
- Date of primary diagnosis in Q3/2021
- Invasive epithelial ovarian cancer, fallopian tube or peritoneal cancer

Exclusion Criteria

- Borderline tumours
- other non-epithelial ovarian malignancies (germ cell tumours, stromal cell tumours, sarcomas)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival

Secondary Outcome Measures

Name	Time	Method
Success of Surgery<br>Primary and Relapse chemotherapy as per the guidelines <br>Relapse-free survival <br>Survival following relapse <br>Time from relapse to first and second subsequent treatments